Sol-Gel Announces Pipeline Update and Future Development Plans apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open)
Endo International plc (NASDAQ: ENDP) (before the market open)
Bio-Techne Corporation (NASDAQ: TECH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Athenex, Inc. (NASDAQ: ATNX) (before the market open)
Zoetis Inc. (NYSE: ZTS) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open)
Share this article
Share this article
NEW YORK, April 28, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ( Sol-Gel or the Company ) (NASDAQ: SLGL) Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Sol-Gel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 27, 2021, Sol-Gel issued a press release announc[ing] an update regarding the U.S. Food and Drug Administration (FDA) approval process for EPSOLAY® (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. The press release stated, in relevant part: In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for EPSOLAY is April 26, 2021. Subsequently, the COVID-19 pandemic restricted the FDA s ability to conduct pre-approval